untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:20:09Z</responseDate>
<request identifier=oai:HAL:inserm-01408002v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:inserm-01408002v1</identifier>
<datestamp>2018-01-12</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-TLSE3</setSpec>
<setSpec>collection:SANTE_PUB_INSERM</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:UNIV-AMU</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:IRD</setSpec>
<setSpec>collection:UCA-TEST</setSpec>
<setSpec>collection:UNIV-COTEDAZUR</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.</title>
<creator>Poizot-Martin, Isabelle</creator>
<creator>Allavena, Clotilde</creator>
<creator>Delpierre, Cyrille</creator>
<creator>Duvivier, Claudine</creator>
<creator>Obry-Roguet, Véronique</creator>
<creator>Cano, Carla E</creator>
<creator>Guillouet De Salvador, Francine</creator>
<creator>Rey, David</creator>
<creator>Dellamonica, Pierre</creator>
<creator>Cheret, Antoine</creator>
<creator>Cuzin, Lise</creator>
<creator>Katlama, Christine</creator>
<creator>Cabié, André</creator>
<creator>Hoen, Bruno</creator>
<contributor>Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM) ; Institut de Recherche pour le Développement (IRD) - Aix Marseille Université (AMU) - ORS PACA - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )</contributor>
<contributor>Service des maladies infectieuses et tropicales [CHU Nantes] ; CHU Nantes</contributor>
<contributor>Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps [Toulouse] ; Université Paul Sabatier - Toulouse 3 (UPS) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Centre d’Infectiologie Necker Pasteur ; CHU Necker - Enfants Malades [AP-HP] - Université Paris Descartes - Paris 5 (UPD5) - Assistance publique - Hôpitaux de Paris (AP-HP)</contributor>
<contributor>Service des maladies infectieuses ; CHU Nice - University Hospital</contributor>
<contributor>Les Hôpitaux Universitaires de Strasbourg (HUS)</contributor>
<contributor>Université Paris Descartes - Paris 5 (UPD5)</contributor>
<contributor>service des maladies infectieuses [Tourcoing] ; Centre Hospitalier de Tourcoing</contributor>
<contributor>Université Pierre et Marie Curie - Paris 6 (UPMC)</contributor>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH [Paris] ; Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service des maladies infectieuses [CHU Pitié-Salêtrière] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Pitié-Salpêtrière [APHP]</contributor>
<contributor>Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane) ; Université des Antilles et de la Guyane (UAG) - Institut National de la Santé et de la Recherche Médicale (INSERM) - CHU de Pointe-à-Pitre - Centre Hospitalier de Cayenne Andrée Rosemon - CHU de Fort de France</contributor>
<contributor>Service des Maladies Infectieuses et Tropicales[Point-à-Pitre] ; CHU Pointe à Pitre</contributor>
<description>International audience</description>
<source>ISSN: 0025-7974</source>
<source>EISSN: 1536-5964</source>
<source>Medicine</source>
<publisher>Lippincott, Williams & Wilkins</publisher>
<identifier>inserm-01408002</identifier>
<identifier>http://www.hal.inserm.fr/inserm-01408002</identifier>
<identifier>http://www.hal.inserm.fr/inserm-01408002/document</identifier>
<identifier>http://www.hal.inserm.fr/inserm-01408002/file/2016%2C%20Poizot-Martin%20-%20First-line%20cART%20regimen%20impacts%20the%20course%20of%20CD8%2B%20T-cell%20counts%20in%20HIV-infected%20patients.pdf</identifier>
<source>http://www.hal.inserm.fr/inserm-01408002</source>
<source>Medicine, Lippincott, Williams & Wilkins, 2016, 95, 〈10.1097/MD.0000000000005087〉</source>
<identifier>DOI : 10.1097/MD.0000000000005087</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MD.0000000000005087</relation>
<language>en</language>
<subject lang=en>CD8</subject>
<subject lang=en>first-line cart</subject>
<subject lang=en>non nucleotide reverse transcriptase inhibitors</subject>
<subject lang=en>CD4:CD8 ratio</subject>
<subject>[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>The aim of the study was to investigate the impact of first-line combined antiretroviral therapy (cART) regimen on the course of CD8 + T-cell counts in human immunodeficiency virus (HIV)-infected patients. A retrospective observational study conducted on the French DAT'AIDS Cohort of HIV-infected patients. We selected 605 patients initiating a first-line cART between 2002 and 2009, and which achieved a sustained undetectable HIV plasma viral load (pVL) for at least 12 months without cART modification. The evolution of CD8 + T-cell counts according to cART regimen was assessed. CD8 + T-cell counts were assessed in 572 patients treated with 2NRTIs+1PI/r (n= 297), 2NRTIs+1NNRTI (n= 207) and 3NRTIs (n= 68). In multivariate analysis, after 12 months of follow-up, the 3NRTIs regimen was associated with a significantly smaller decrease of CD8 + T-cell count compared with NNRTI-containing regimens (–10.2 cells/mL in 3NRTIs vs –105.1 cells/mL; P=0.02) but not compared with PI-containing regimens (10.2 vs –60.9 cells/mL; P=0.21). After 24 months, the 3NRTIs regimen was associated with a smaller decrease of CD8 + T-cell count and % compared with PI/r-and NNRTI-containing regimens (0.2 in 3NRTIs vs –9.9 with PI/r-regimens, P=0.001, and vs –11.1 with NNRTI-regimens, p < 0.0001). A focus analysis on 11 patients treated with an INSTI-containing cART regimen during the study period showed after 12 months of follow-up, a median decrease of CD8 + T-cell count of –155 [inter quartile range: –302; –22] cells/mL. Our data highlight the fact that cART regimens have differential effects on CD8 pool down regulation. Abbreviations: cART = combined antiretroviral therapy, HIV = human immunodeficiency virus, INSTI = integrase strand transfer inhibitor, NNRTI = non-nucleotide reverse transcriptase inhibitor, NRTI = nucleotide reverse transcriptase inhibitor, PI/r = Ritonavir-boosted protease inhibitor, pVL = plasma viral load.</description>
<date>2016-10-14</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
